Scientists have discovered that combinations of toxin-blocking proteins found in rattlesnake blood can powerfully neutralize venom from several dangerous snake species. In laboratory tests, these protein mixtures were approximately ten times more potent than a current commercial antivenom. This finding could lead to a new generation of nature-inspired snakebite treatments.
Researchers at the University of Maryland identified these proteins. Their study focused on the western diamondback rattlesnake's natural defenses against its own venom. The team combined specific proteins from rattlesnake blood to achieve strong protection against various venoms.
Snakebite is a significant global health issue. The World Health Organization estimates that venomous snakes kill between 80,000 and 140,000 people annually. Hundreds of thousands more survivors experience permanent disabilities. Current antivenoms, typically produced by exposing large animals to venom, have limitations. These include variable effectiveness, high manufacturing costs, and potential for severe immune reactions in patients.
The research, published in the *Proceedings of the National Academy of Sciences*, built on earlier work identifying a protein called FETUA-3. This protein blocks metalloproteinase toxins in rattlesnake venom. The new study found that while individual FETUA proteins offered some protection, combinations were far more effective. Optimized combinations neutralized the lethal effects of rattlesnake venom and protected against venom from multiple viper species.
This approach targets metalloproteinases, one family of venom toxins. Scientists are now applying this strategy to other toxin families. The first commercial applications of these nature-based antivenoms may be in veterinary medicine. Treatments for human snakebites could follow. These new antivenoms aim to be safer, less expensive, and easier to manufacture on a large scale.
Related stories
Dreaming May Deplete Brain Energy Despite Increased Fuel Supply
New research indicates that dreaming during REM sleep may consume significant brain energy, with neuronal energy levels dropping despite an increase in the brain's fuel supply.
Tirzepatide May Activate Calorie-Burning Brown Fat
A mouse study suggests tirzepatide, sold as Mounjaro and Zepbound, may activate calorie-burning brown fat, offering a new understanding of its metabolic benefits.
ADHD and Autism Diagnoses Show Shifting Demographics in Denmark
A large Danish study found that children diagnosed with ADHD or autism now more closely resemble the general population, suggesting broader identification rather than only an increase in underlying conditions.